ME02102B - Novi polimorf - Google Patents
Novi polimorfInfo
- Publication number
- ME02102B ME02102B MEP-2015-56A MEP5615A ME02102B ME 02102 B ME02102 B ME 02102B ME P5615 A MEP5615 A ME P5615A ME 02102 B ME02102 B ME 02102B
- Authority
- ME
- Montenegro
- Prior art keywords
- solid form
- form according
- nocturia
- vasopressin
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Claims (11)
1.Čvrsti oblik 1-(2-metil-4-(2,3,4,5-tetrahidro-1-benzazepin-1-ilkarbonil)benzilkarbamoil)-L-prolin-N,N-dimetilamida, koji pokazuje najmanje slijedecće karakteristične XRF pikove difrakcije praha (Cu Kα zračenje, izraženo u stupnjevima 2θ) na približno 5.5, 10.9, 14.2, 21.9 i 24.0.
2.Čvrsti oblik prema zahtjevu 1 koji ima rendgenski difraktogram u suštini isti kao onaj prikazan na slici 1.
3.Čvrsti oblik prema zahtjevima 1 ili 2 naznačen IR spektrom koji ima pikove izraženo u cm-1 na približno 3525, 3425, 2932, 2873, 2135, 1958, 1925, 1631, 1529, 1489, 1439, 1377, 1355, 1311, 1260, 770, 743.
4.Čvrsti oblik prema bilo kojem od zahtjeva 1 do 3 koji ima IR spektar u suštini isti kao onaj prikazan na slici 3.
5.Čvrsti oblik prema bilo kojem od patentnih zahtjeva 1 do 4 koji je hidrat.
6.Čvrsti oblik prema zahtjevu 5, naznačen time što hidrat predstavlja monohidrat.
7.Farmaceutski sastav koji sadrži čvrsti oblik prema bilo kojem od zahtjeva 1 do 6, ili njegov solvat, zajedno sa farmaceutski prihvatljivim adjuvansom, diluentom ili nosačem.
8.Čvrsti oblik prema bilo kojem od zahtjeva 1 do 6, ili njegov solvat, za upotrebu u terapiji.
9.Čvrsti oblik prema bilo kojem od zahtjeva 1 do 6, ili njegov solvat, za upotrebu u liječenju bolesti ili stanja posredovanog vazopresin V2 receptorima.
10.Čvrsti oblik za upotrebu prema zahtjevu 9, naznačen time što je oboljenje ili stanje posredovano vazopresin V2 receptorima izabrano između nocćnog mokrenja, nokturije, poliurije uslijed centralnog dijabetesa insipidusa, urinarne inkontinencije i poremećaja krvarenja.
11.Čvrsti oblik za upotrebu prema zahtjevu 9, naznačen time što je oboljenje ili stanje posredovano vazopresin V2 receptorima nokturija.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1005623.2A GB201005623D0 (en) | 2010-04-01 | 2010-04-01 | New polymorph |
| US34704810P | 2010-05-21 | 2010-05-21 | |
| EP11714079.8A EP2552910B1 (en) | 2010-04-01 | 2011-03-31 | New polymorph |
| PCT/GB2011/000500 WO2011121308A1 (en) | 2010-04-01 | 2011-03-31 | New polymorph |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02102B true ME02102B (me) | 2015-10-20 |
Family
ID=42228830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-56A ME02102B (me) | 2010-04-01 | 2011-03-31 | Novi polimorf |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9079881B2 (me) |
| EP (1) | EP2552910B1 (me) |
| JP (1) | JP5802737B2 (me) |
| KR (1) | KR101792621B1 (me) |
| CN (1) | CN102918038B (me) |
| CA (1) | CA2795109C (me) |
| DK (1) | DK2552910T3 (me) |
| ES (1) | ES2538085T3 (me) |
| GB (1) | GB201005623D0 (me) |
| HR (1) | HRP20150513T1 (me) |
| HU (1) | HUE026442T2 (me) |
| ME (1) | ME02102B (me) |
| MX (1) | MX2012011382A (me) |
| PL (1) | PL2552910T3 (me) |
| PT (1) | PT2552910E (me) |
| RS (1) | RS53956B1 (me) |
| RU (1) | RU2559633C2 (me) |
| SI (1) | SI2552910T1 (me) |
| SM (1) | SMT201500107B (me) |
| WO (1) | WO2011121308A1 (me) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201105537D0 (en) * | 2011-03-31 | 2011-05-18 | Vantia Ltd | New process |
| CN103755707B (zh) * | 2013-09-17 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅱ及其制备方法和用途 |
| CN104059070B (zh) * | 2013-09-17 | 2016-02-10 | 天津药物研究院有限公司 | 利希普坦晶型ⅰ及其制备方法和用途 |
| CN103694240B (zh) * | 2013-09-18 | 2015-11-18 | 天津药物研究院 | 利希普坦的溶剂合物及其制备方法和用途 |
| CN104140429B (zh) * | 2014-07-25 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅴ及其制备方法和用途 |
| CN119390667A (zh) * | 2015-07-22 | 2025-02-07 | 阿纳韦克斯生命科学公司 | 四氢-n,n-二甲基-2,2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 |
| WO2020154581A1 (en) | 2019-01-24 | 2020-07-30 | Assia Chemical Industries Ltd | Solid state forms of fedovapagon-salicyclic acid co-crystal |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW359669B (en) | 1995-12-15 | 1999-06-01 | Otsuka Pharma Co Ltd | Benzazepine derivatives |
| SI1000062T1 (en) | 1997-07-30 | 2004-12-31 | Wyeth | Tricyclic vasopressin agonists |
| NZ502448A (en) | 1997-07-30 | 2002-12-20 | Wyeth Corp | Tricyclic vasopressin agonists and medicaments containing these compounds |
| ATE229528T1 (de) | 1999-02-04 | 2002-12-15 | Wyeth Corp | Pyrrolobenzodiazepine carboxamide vasopressin agonisten |
| WO2000046227A1 (en) | 1999-02-04 | 2000-08-10 | American Home Products Corporation | Thienylbenzoylbenzazepines as vasopressin agonists |
| CN1339035A (zh) | 1999-02-04 | 2002-03-06 | 美国家用产品公司 | 吡啶并苯并二吖庚因和吡啶并苯并氧杂吖庚因酰胺血管加压素激动剂 |
| WO2000046224A2 (en) | 1999-02-04 | 2000-08-10 | American Home Products Corporation | Tricyclic pyridine n-oxides vasopressin agonists |
| GB0000079D0 (en) * | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| GB0015601D0 (en) | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
-
2010
- 2010-04-01 GB GBGB1005623.2A patent/GB201005623D0/en not_active Ceased
-
2011
- 2011-03-31 JP JP2013501934A patent/JP5802737B2/ja not_active Expired - Fee Related
- 2011-03-31 RU RU2012146544/04A patent/RU2559633C2/ru not_active IP Right Cessation
- 2011-03-31 SI SI201130487T patent/SI2552910T1/sl unknown
- 2011-03-31 HR HRP20150513TT patent/HRP20150513T1/hr unknown
- 2011-03-31 DK DK11714079T patent/DK2552910T3/en active
- 2011-03-31 RS RS20150258A patent/RS53956B1/sr unknown
- 2011-03-31 US US13/637,873 patent/US9079881B2/en not_active Expired - Fee Related
- 2011-03-31 ES ES11714079.8T patent/ES2538085T3/es active Active
- 2011-03-31 WO PCT/GB2011/000500 patent/WO2011121308A1/en not_active Ceased
- 2011-03-31 KR KR1020127028111A patent/KR101792621B1/ko not_active Expired - Fee Related
- 2011-03-31 PT PT117140798T patent/PT2552910E/pt unknown
- 2011-03-31 ME MEP-2015-56A patent/ME02102B/me unknown
- 2011-03-31 CN CN201180026714.4A patent/CN102918038B/zh not_active Expired - Fee Related
- 2011-03-31 EP EP11714079.8A patent/EP2552910B1/en active Active
- 2011-03-31 HU HUE11714079A patent/HUE026442T2/en unknown
- 2011-03-31 CA CA2795109A patent/CA2795109C/en not_active Expired - Fee Related
- 2011-03-31 PL PL11714079T patent/PL2552910T3/pl unknown
- 2011-03-31 MX MX2012011382A patent/MX2012011382A/es active IP Right Grant
-
2015
- 2015-05-05 SM SM201500107T patent/SMT201500107B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013523706A (ja) | 2013-06-17 |
| RS53956B1 (sr) | 2015-08-31 |
| MX2012011382A (es) | 2013-01-29 |
| CA2795109C (en) | 2018-04-17 |
| US20140296213A1 (en) | 2014-10-02 |
| SI2552910T1 (sl) | 2015-06-30 |
| SMT201500107B (it) | 2015-07-09 |
| PL2552910T3 (pl) | 2015-07-31 |
| EP2552910A1 (en) | 2013-02-06 |
| KR20130023218A (ko) | 2013-03-07 |
| PT2552910E (pt) | 2015-05-13 |
| RU2012146544A (ru) | 2014-05-10 |
| RU2559633C2 (ru) | 2015-08-10 |
| DK2552910T3 (en) | 2015-04-07 |
| KR101792621B1 (ko) | 2017-11-02 |
| ES2538085T3 (es) | 2015-06-17 |
| CN102918038B (zh) | 2015-09-09 |
| JP5802737B2 (ja) | 2015-11-04 |
| EP2552910B1 (en) | 2015-03-11 |
| CN102918038A (zh) | 2013-02-06 |
| HUE026442T2 (en) | 2016-06-28 |
| HRP20150513T1 (hr) | 2015-06-05 |
| GB201005623D0 (en) | 2010-05-19 |
| CA2795109A1 (en) | 2011-10-06 |
| US9079881B2 (en) | 2015-07-14 |
| WO2011121308A1 (en) | 2011-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02102B (me) | Novi polimorf | |
| EP3954395A4 (en) | Pharmaceutical composition for muscle disease treatment | |
| GB2586940B (en) | Therapeutic compositions | |
| IL260297A (en) | Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide | |
| NZ603043A (en) | Pharmaceutical compositions comprising cftr modulators and administrations thereof | |
| PL2054411T3 (pl) | Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne | |
| EP4574210A3 (en) | Kappa opioid receptor antagonists and products and methods related thereto | |
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| JP2012036197A5 (me) | ||
| MX2012012571A (es) | Dicarboxamidas de ciclopropilo y analogos que muestran actividades anti-cancerosas y anti-proliferativas. | |
| WO2011150156A3 (en) | Heteroaryl compounds and methods of use thereof | |
| JP2017514910A5 (me) | ||
| JP2014507446A5 (me) | ||
| PH12015500460B1 (en) | Coated pharmaceutical composition containing regorafenib | |
| HRP20192132T1 (hr) | Antagonist nk-1/nk-3 receptora za liječenje valunga | |
| MX363127B (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| WO2012096929A3 (en) | Heteroaryl compounds and methods of use thereof | |
| WO2013188273A8 (en) | Topical ophthalmological pharmaceutical composition containing axitinib | |
| GB202006899D0 (en) | Reduction of the effects of latency for extended rality experiences | |
| GEP201606526B (en) | 5-ht3 receptor antagonists | |
| NZ605431A (en) | D2 antagonists, methods of synthesis and methods of use | |
| JP2013507408A5 (me) | ||
| WO2014059232A3 (en) | Substituted spiropiperidinyl compounds useful as gpr120 agonists | |
| WO2013188268A8 (en) | Topical ophthalmological pharmaceutical composition containing pazopanib | |
| GEP20207098B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |